RNA-guided transcriptional regulation and methods of using the same for the treatment of back pain
Described herein are compositions and methods for treatment and prevention of low back pain. The compositions include vectors comprising nucleotide sequences encoding one or more CRISPR-Cas system guide RNAs and a RNA-directed nuclease. The methods include modulating expression of a gene in a cell using said compositions, introducing a CRISPR-Cas system into a cell comprising one or more vectors comprising said compositions, inducing site-specific DNA cleavage in a cell, and treating a subject having lower back pain, and lower back pain caused by degenerative disc disease using the compositions disclosed herein.
1. A CRISPR-Cas system comprising one or more vectors comprising:
a) a promoter operably linked to a nucleotide sequence encoding a CRISPR-Cas system guide RNA (gRNA); and
b) a regulatory element operably linked to a nucleotide sequence encoding a RNA-directed nuclease,
wherein the gRNA comprises:
a gRNA sequence having the sequence of SEQ ID NOs: 63, 61, 62 or 64;
a gRNA sequence having the sequence of SEQ ID NOs: 79, 80, 81, 82 or 83; and
a gRNA sequence having the sequence of SEQ ID NOs: 85, 84, 86, 87, 88, or 89.
2. The CRISPR-Cas system of claim 1 , wherein the RNA-directed nuclease is a dCas9 protein.
3. The CRISPR-Cas system of claim 2 , wherein the Cas9 protein is codon optimized for expression in the cell.
4. The CRISPR-Cas system of claim 1 , wherein the cell is a mammalian or human cell; and/or a mesenchymal stem cell.
5. The CRISPR-Cas system of claim 1 , wherein the system is packaged into a single lentiviral, adenoviral or adeno-associated virus particle.
6. A vector comprising:
a) a promoter operably linked to a nucleotide sequence encoding a CRISPR-Cas system guide RNA (gRNA); and
b) a regulatory element operably linked to a nucleotide sequence encoding a RNA-directed nuclease;
wherein the gRNA comprises:
a gRNA sequence having the sequence of SEQ ID NOs: 63, 61, 62 or 64;
a gRNA sequence having the sequence of SEQ ID NOs: 79, 80, 81, 82 or 83; and
a gRNA sequence having the sequence of SEQ ID NOs: 85, 84, 86, 87, 88, or 89.
7. The vector of claim 6 , wherein components a) and b) are located on the same or different vectors of the same system.
8. The vector of claim 6 , wherein the RNA-directed nuclease is a dCas9 protein.
9. The vector of claim 6 , wherein the cell is a mammalian or human cell; and/or a mesenchymal stem cell.
10. A method of modulating expression of a gene in a cell, the method comprising:
introducing into the cell CRISPR-Cas system comprising one or more vectors comprising: a) a promoter operably linked to a nucleotide sequence encoding a CRISPR-Cas system guide RNA (gRNA); and b) a regulatory element operably linked to a nucleotide sequence encoding a RNA-directed nuclease,
wherein the gRNA comprises:
a gRNA sequence having the sequence of SEQ ID NOs: 63, 61, 62 or 64;
a gRNA sequence having the sequence of SEQ ID NOs: 79, 80, 81, 82 or 83; and
a gRNA sequence having the sequence of SEQ ID NOs: 85, 84, 86, 87, 88, or 89.
11. A pharmaceutical composition comprising the nucleic acid sequence of claim 1 .
12. The pharmaceutical composition of claim 11 , wherein the composition comprises a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier comprises a lipid-based or polymer-based colloid.
14. The pharmaceutical composition of claim 11 , wherein the composition is formulated for intervertebral administration.
15. A method of treating a subject having lower back pain, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 11 .
16. The method of claim 15 , wherein in the lower back pain is caused by degenerative disc disease.
17. The method of claim 15 , wherein the composition is administered into or adjacent to the intervertebral disc.
18. The method of claim 15 , further comprising:
determining TNF, IL1, IL6, IL9, IFN-gamma, and/or IL17 levels in the subject prior to the administration step.